ExpressionEdits
Proteins are a foundational pillar in healthcare and behind every major advancement in biotech and synthetic biology for the last half-century, while biotech’s emergence as a new class of therapeutics was driven by the ability to produce proteins using cells or organisms in a controlled manner. Transgenes, artificial gene constructs designed to produce protein, are the basic building-blocks in modern biotechnology, including recombinant protein-based therapeutics, gene and cell therapies, DNA vaccines, food protein production, and more. Despite this essential role, current transgene design dates back to the 1970s and there has been little improvement in the fundamental systems behind it, leading to insufficient protein production, a key challenge for the biotechnology industry.
The ExpressionEdits team have redesigned transgenes from first principles and are building a bioinformatics platform to leverage their unique DNA intronization technology (which uses the non-coding regions of DNA called introns) to achieve an order of magnitude improvement in protein expression. The founders, Kärt Tomberg, Liliana Antunes and Allan Bradley, have worked together for the last 2 years in Allan’s lab at Cambridge University to mimic nature and, by introducing introns in mammalian cells initially, are fundamentally redefining the role of non-coding DNA in protein production and creating significant improvements in protein production.
Our Thesis
Increasing protein expression in eukaryotic systems has boundless applications throughout the industry, ranging from antibody manufacturing to biochemical synthesis to novel in vivo and ex vivo therapies to the wider synthetic biology industry. Therapeutic markets in these areas range from over $200 billion for antibodies and recombinant proteins to $40 billion for cell and gene therapies. We believe that the ExpressionEdits platform can become the fabric for any protein expression system, from antibody manufacturing to in vivo therapeutics. The most exciting early applications, and where ExpressionEdits will eventually build an internal pipeline, are potentially in recombinant protein or gene therapies that involve complex diseases with particularly hard-to-express proteins.
We’re excited to be backing Kärt and the entire ExpressionEdits team on their ambitious mission.
—
Disclaimer: The information contained in this article has been prepared solely for informational purposes and is not an offer to sell or a solicitation of an offer to purchase an interest in any entity managed by BlueYard Capital (“BlueYard”). Any reference to a specific company or security does not constitute a recommendation to buy, sell, hold, or directly invest in the company or its securities. It may not be modified, reproduced, or redistributed in whole or in part without the prior written consent of BlueYard. Portfolio company information presented herein is for informational purposes only and not intended to be a guarantee of certain investment results. BlueYard does not represent that the information herein is accurate, true, or complete, makes no warranty, express or implied, regarding the information herein and shall not be liable for any losses, damages, costs, or expenses relating to its adequacy, accuracy, truth, completeness, or use. All other company, product and service names or service marks of others and their use does not imply their endorsement of, or an association with this program.
